Inspiring Results For Phase III Disease-Modifying Cystic Fibrosis Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
Inspire Pharmaceuticals' denufosol showed improvement in FEV1 versus placebo over 24 weeks.
You may also be interested in...
Stockwatch: The TIGER That Came To Lilly
The reasons behind Lilly's latest clinical failure had much less to do with the indication and more to do with repeating the past mistakes of Inspire and Sunesis. Unfortunately, that same die has already been cast for the trials of Biogen and Ophthotech that are due to report imminently.
Inspire Extends Treatment In Phase III Trial For Disease-Modifying CF Candidate
Open-label safety extension of earlier Phase III study shows progressive improvement from baseline over time.
Inspire Extends Treatment In Phase III Trial For Disease-Modifying CF Candidate
Open-label safety extension of earlier Phase III study shows progressive improvement from baseline over time.